Northern Norway Regional Health Authority   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bodø Norway (2002)

Organization Overview

First Clinical Trial
2004
NCT00159510
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Helse Nord | Helse Nord-Trøndelag HF

Active Ingredients

Drugs in Phase 4 Trials (2)

medroxyprogesterone (provera) (1 trial)

norgestrel (Ovral) (1 trial)

Drugs in Phase 3 Trials (3)

misoprostol (cytotec) (1 trial)

onabotulinumtoxinA (Botox) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (1)

atezolizumab (tecentriq) (1 trial)

Drugs in Phase 1 Trials (2)

methylene blue (proveblue) (1 trial)

nitric oxide (inomax) (1 trial)

Drugs in Other Trials (1)

human fecal microbiota (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Endometrial Hyperplasia (Phase 4)

Hyperplasia (Phase 4)

Lung Injury (Phase 1)

Respiratory Distress Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9